Sign inJoin waitlistJoin the waitlist

Mark Ranalli

Physician · Nationwide Children's Hospital

Credentials: · ·

History

Nationwide Children's Hospital
2021–Present

Ann & Robert H Lurie Children's Hospital of Chicago
1992–1993
Pediatrics
Children's Hospital of Philadelphia
1989–1992
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
1985–1989

Research

Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity
Journal of Cell Science · 2001 · 147 citations
Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia
Bone · 2008 · 64 citations
Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy
Review · Pediatric Blood & Cancer · 2015 · 62 citations

Jennifer Aldrink
16 papers
Micah Skeens
6 papers
Keri Streby
5 papers · 1 as a fellow
Nilay Shah
5 papers
Sara Mansfield
4 papers · 2 as a fellow
Shachi Srivatsa
4 papers · 4 as a resident
Bhuvana Setty
3 papers
Elizabeth Mullen
3 papers
Frank Balis
3 papers
Joanne Lagmay
3 papers · 3 as a fellow
Kathleen Schieffer
3 papers
LG
Lindsay Gil
3 papers · 3 as a resident

Clinical trials

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Principal investigator · Active not recruiting · Phase 1, Phase 2
Nationwide Children's Hospital
2022–2027
MIBG Therapy for Patients With MIBG Avid Tumors
Principal investigator · Active not recruiting · Phase 2
Nationwide Children's Hospital
2014–2025
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Study chair · Recruiting · Phase 2
New Approaches to Neuroblastoma Therapy Consortium
2024–2038
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030